Henry Skinner, PhD, MJur, is the CEOof the AMR Action Fund. He is an experienced executive who is deeply versed inthe economic and scientific challenges of antimicrobial drug development. Priorto joining the Fund, he held leadership positions across the pharmaceutical andventure capital sectors, including serving as Senior Vice President, Venture atTekla Capital Management and as Deputy Head and Managing Director of theNovartis Venture Fund. Henry was a postdoctoral fellow at Baylor College ofMedicine in the department of Human and Molecular Genetics. He holds a PhD inMicrobiology and an MS in Biochemistry from the University of Illinois; an MJurin Health Law, Policy, and Management from Texas A&M; and an MS and a BS inBiology/Biotechnology from Worcester Polytechnic Institute.
